Kaposi sarcoma (KS) remains one of the most prevalent malignancies associated with human immunodeficiency virus (HIV)-infected individuals in sub-Saharan African countries, such as Zambia. KS is the leading cancer in both incidence and mortality among Zambian men and the third leading cancer among Zambian women, behind cervical and breast cancers [1] .
Immune suppression, resulting from age, anti-transplant rejection therapy, and T-cell depletion, is associated with classical, iatrogenic, and AIDS-associated forms of KS, respectively [2] [3] [4] [5] . The etiological agent of KS is now known to be KS-associated herpesvirus (KSHV), also known as human herpesvirus . KSHV is the most recently discovered human herpesvirus and is a member of the gamma-herpesvirus or lymphocryptovirus subgroup, along with Epstein-Barr virus (EBV). KSHV was first identified in AIDS-associated KS lesions, by representational difference analysis [6] . It was also found to be associated with 2 other lymphoproliferative disorders, primary effusion lymphoma and multicentric Castleman disease, an inflammatory disease associated with HIV-infected individual [7, 8] . Like other herpesviruses, KSHV exhibits 2 distinct phases of infection: lytic replication and latency. During latency, the gene expression pattern is thought to promote immune evasion, prevent programmed cell death, and enable the virus to establish a persistent infection [9] [10] [11] [12] [13] . Lytic reactivation leads to virus production, which enables the spread of viruses from infected tissue compartments into the periphery. This, in turn, leads to viremia and to increased potentials for HSHV transmission and KS development [14, 15] .
The association of KS development with various forms of immune suppression suggests that immune surveillance is an essential component in limiting KSHV-induced pathogenesis. The precise nature of the immune response necessary to prevent KS remains unclear, but it is evident that the virus can establish persistent infection in different cell types and encodes a number of immunomodulatory proteins that support KSHV persistence, replication, and transmission [11, [16] [17] [18] [19] [20] [21] [22] . One incompletely defined component of KSHV infection is an understanding of tissue locations where the virus has the potential to persist. The central nervous system (CNS) is one such location and where a number of other human herpesviruses have been shown to persist [23] .
The known cellular tropism for KSHV includes endothelial, epithelial, and B cells and, perhaps, macrophages [7, 17, 20, [23] [24] [25] [26] [27] , but since most herpesviruses demonstrate some degree of neurotropism, we sought to determine whether KSHV can establish infection in parenchymal cells of the CNS. Previous reports suggested the detection of viral nucleic acids in CNS samples, but these findings could be confounded by virus in immune cells circulating through brain vasculature [28] [29] [30] [31] [32] [33] . We now report that KSHV can be detected in various brain tissues from individuals for whom KSHV infection was confirmed on the basis of KSHV DNA detection by PCR or KSHV seropositivity was confirmed on the basis of immunofluorescence assay (IFA) of serum or cerebrospinal fluid (CSF) samples. These individuals were also HIV coinfected. KSHV CNS infection was found to be latent, as indicated by expression of latency-associated nuclear antigen (LANA), and the majority of infected cells were identified as neurons. This result was recapitulated in infection of mixed primary human neuron cultures in vitro. Our results indicate that KSHV can gain entry into the CNS and infect neurons in HIV-positive patients. To our knowledge, this is the first study to demonstrate in vivo infection of human neurons by KSHV.
METHODS

Patient Samples
Autopsy samples were collected at the University Teaching Hospital in Lusaka, Zambia, from HIV-positive patients and HIV-negative patients. Consent was obtained from families of the deceased patients prior to specimen collection. Sample sets included frozen and formalin-fixed paraffin-embedded tissue from the frontal lobe, parietal lobe, temporal lobe, occipital lobe, hippocampus, cerebellum, and basal ganglia. CSF and plasma specimens were collected where possible.
HIV Serological Testing
Blood was screened in Zambia for HIV-specific antibodies, using HIV rapid serologic tests (Abbott-Determine and Unigold) according to the manufacturer's instructions.
DNA Extraction From Postmortem Tissue Specimens
Fresh-frozen tissue specimens (weight, 100 mg) were pulverized by cryo-cracking with liquid nitrogen. Cells were lysed using QIAzol lysis reagent (Qiagen, Hilden, Germany) according to manufacturer's protocol, with the following modifications. The upper aqueous phase was discarded after chloroform extraction. To precipitate the DNA, 100% ethanol was added to the lower organic phase. The DNA pellet was washed twice with 0.1 M sodium citrate, followed by another wash with 75% ethanol, and was air dried. The final extracted DNA was dissolved in Tris-ethylenediaminetetraacetic acid (TE) buffer and incubated at 65˚C for 1 hour, followed by incubation overnight at room temperature. 
PCR for
Southern Blot for Detection of KSHV ORF26 and LANA
To confirm PCR detection of KSHV ORF26 and LANA in brain tissue specimens, Southern blots with digoxigenin (DIG)-labeled ORF26 and LANA DNA probes were performed. The probes were prepared by amplifying BC-3 genomic DNA with primers 5′-CGAATCCAACGGATTTGACCTC-3′ (KS-4) and 5′-CCCATAAATGACACATTGGTGGTA-3′ (KS-5) for ORF26 and 5′-AGGACTAGACACAAATGCTGG-3′ (NLana_2F) and 5′-AAACGAAACAGGTCTCCGG-3′ (NLana_2R) for LANA, using the PCR DIG Probe Synthesis Kit (Roche, Basel, Switzerland ) according to the manufacturer's protocol. Ten microliters of first-round ORF26 PCR and 10 μL of second-round LANA PCR amplification products were analyzed by standard Southern blot with overnight hybridization at 42°C. Two stages of stringent washes were performed after hybridization to remove unbound probe and incomplete or off-target hybridizations. Hybridized probes were detected with alkaline phosphatase-conjugated anti-DIG antibody and BCIP/NBT chromagen deposition reagent (DIG DNA Labeling and Detection Kit; Roche).
IFA
An IFA using KSHV-infected BC3 cells was used to detect KSHV seropositivity in all sampled individuals as previously described [37] . Briefly, 1 × 10 4 BC3 cells per well were spotted onto 12-well slides. Plasma or CSF samples obtained from autopsied subjects or HIV/KSHV-negative controls were diluted at 1:40, added to the affixed BC3 cells, and incubated at 37°C for 30 minutes. Slides were washed and incubated with murine α-human immunoglobulin G (IgG) antibody at 37˚C for 30 minutes. Slides were washed and incubated with donkey α-mouse IgG antibody conjugated to DyLight 488 at 37˚C for 30 minutes. Slides were washed and counterstained with 0.004% Evans blue for 5 minutes, and each slide was read independently by 2 laboratory workers. A sample was considered KSHV seropositive if concordant results were reported from both readers. Owing to postmortem blood clotting, plasma samples were not collectable for all subjects (Table 1) .
KSHV LANA and K8.1 Immunohistochemical (IHC) Analysis
Formalin-fixed, paraffin-embedded brain tissue specimens from HIV-positive Zambian individuals were divided into 5-μm sections. Slides were deparaffinized and rehydrated by means of standard xylene and ethanol washes. Endogenous peroxidase activity was blocked using a hydrogen peroxide-methanol solution, and antigen retrieval was performed in sodium citrate solution at 98°C for 15 minutes. Slides were blocked with 10% normal goat serum in 1X PBS and incubated overnight at 4°C with murine anti-LANA monoclonal antibody (kindly provided by Dr Bala Chandran, Rosalind Franklin University of Medicine and Science, Chicago, IL) at a dilution of 1:750 for KSHV LANA protein detection or with murine anti-K8.1 monoclonal antibody (Advanced Biotechnologies, Eldersburg, MD) at the manufacturer's recommended dilution for KSHV K8.1 protein detection. Slides were washed and incubated with horseradish peroxidase (HRP)-labeled polymeric anti-mouse secondary antibody (Dako, Santa Clara, CA). Diaminobenzidine (Dako) and hematoxylin were used for chromogen deposition and counterstaining, respectively.
Cell Lineage and KSHV Immunofluorescence-Based Detection
Dual-staining immunofluorescence (IF)-based detection was performed using a primary antibody mixture of mouse anti-KSHV LANA (as described above in the section titled "IFA") and various anti-human cell lineage-specific antisera. The lineage-specific antisera included polyclonal rabbit antisera against feminizing locus on X-3, Fox-3/ hexaribonucleotide binding protein- , and cluster of differentiation 45 (CD45) (Dako, 1:500). These reagent identified neurons, astrocytes, oligodendrocytes, microglia/macrophages, B cells, endothelial cells, and lymphocytes, respectively. Slides were incubated overnight with primary antibodies at 4˚C in Tris-NaCl blocking buffer (TNB). After 3 washes with TNB, the slides were stained with donkey anti-rabbit AlexaFluor 488 and anti-mouse AlexaFluor 647 
Recombinant KSHV Production and Primary Human Neuron Infection
Recombinant KSHV (rKSHV.219) that expresses green fluorescent protein (GFP) under the cellular EF-1α promoter and red fluorescent protein (RFP) under the viral lytic PAN promoter was produced as previously described [34] . Briefly, Vero.219 cells, which encode the recombinant KSHV, were infected with a KSHV RTA-expressing baculovirus for 4 hours, followed by overnight stimulation with 1.25 mM sodium butyrate. Cells were then washed and incubated with fresh growth medium for 72 hours before the supernatant was filtered (pore size, 0.45 µm) and collected. The rKSHV.219 virus titer was then determined using 293-T cells according to the standard Reed Muench method [35] . Neurons were obtained from the Comprehensive NeuroAIDS Center at Temple University (Philadelphia, PA). The single-cell suspension was plated at a density of 1.8 × 10 6 cells/60-mm poly-D lysine-coated dish and cultured in neurobasal medium with B27 supplement, horse serum, and gentamicin (NM5). After 2 hours, medium was changed, and unattached cells were discarded. Twenty-four hours later, cultures were refed with a complete change of NM5 lacking horse serum (NM0). Four days later, 25% of the medium was removed and replaced with NM0 supplemented with fluoro-deoxyuridine and uridine (dilution 1:4000) for 4 days. Cells were then cultured in NM0, with 25% of the medium changed every third day, and maintained for 2-3 weeks until infection with virus. Purity of neuronal cultures was assessed by immunolabeling with anti-MAP2 and neurofilament for detection of neurons. Neural cultures were infected with rKSHV.219 at multiplicity of infection of 0.5 for 72 hours prior to evaluation by microscopy or processing for IF-based detection of antigens.
RESULTS
Given the adult KSHV seroprevalence in Zambia of 48% [36] [37] [38] , with an even higher prevalence among HIV-infected individuals, and the demonstrated neurotropism of many other members of the Herpesviridae family, we worked closely with colleagues at the University Teaching Hospital to initiate collection of postmortem brain tissue specimens to determine whether KSHV could be directly detected in the brain parenchyma. Formalin-fixed, paraffin-embedded, and fresh-frozen tissue specimens were collected and analyzed. We first examined the brain tissue specimens from an HIV-positive individual who did not have cutaneous or visceral KS (subject 116; Table 1 ). To investigate whether KSHV infects the CNS and whether it exhibits regional or cellular tropism, DNA was extracted from various frozen brain tissue specimens, including the frontal, temporal, parietal, and occipital lobes; the basal ganglion; the hippocampus; and the cerebellum. The extracted DNA was amplified by primers specific for KSHV capsid protein, encoded by ORF26. We found that tissue specimens from different brain regions of subject 116 were positive for KSHV by PCR, and the results were confirmed by Southern blot analysis using a KSHV-specific ORF26 probe ( Figure 1A) . The presence of KSHV DNA was further confirmed for cerebellum and hippocampus tissue specimens from subject 116, using PCR specific for KSHV LANA, followed by Southern blot confirmation with a KSHV LANA-specific probe.
Since the brain is a highly vascular organ and because KSHV is known to have tropism for B cells that comprise approximately 5%-10% of blood leukocytes, it remained possible that detection of KSHV resulted from amplification of viral sequences in vascular cells. Alternately, KSHV could be present in the brain parenchyma, either in extravasating immune cells or in CNSresident cell types. To discriminate between these possibilities, we tested for the presence of LANA antigen in the PCR-positive brain tissue specimens, since it is the primary KSHV protein expressed during latency [9, 12, 13] . LANA localization is typically nuclear, and its staining pattern is typically punctate [39, 40] , although recent reports suggest some isoforms with alternative subcellular localization [41] . Robust expression of KSHV LANA was detected in subject 116. An example of the KSHV detection by IHC analysis in the cerebellar tissue is shown in Figure 1B , together with specificity controls. Surprisingly, we detected very little KSHV antigen localized to brain vasculature ( Figure 1C ). Rather, labeling was evident, although sparse, in various regions of the parenchyma and highest in the gray matter, where the larger proportion of brain cell soma are localized. In the cerebral cortex, KSHV latent antigen was localized to cells in the deeper gray matter, near the white matter border. A representative panel of KSHV LANA staining by IHC analysis in the sampled brain tissue specimens for subject 116 is shown in Figure 1D . Despite staining of adjacent or near-adjacent sections, expression of the KSHV lytic antigen K8.1 was not detected in any brain tissue (data not shown).
To confirm that KSHV can be found in brain tissues of other infected individuals, we further analyzed brain tissue specimens from 10 additional HIV/KSHV-coinfected individuals, a KSHV-seronegative but HIV-positive individual (subject 231), and a KSHV-seronegative, HIV-negative individual (subject 001; Table 1 ). Interestingly, unlike subject 116, no KSHV was detected in the CNS from a number of KSHV-seropositive subjects, whereas for others, such as subject 92, only specimens from certain tissues (ie, the occipital lobe, hippocampus, and cerebellum) were found to be PCR positive. The PCR-positive results were confirmed by IHC analysis, and an example of the Figure 2 . Similar to subject 116, there was high expression of LANA in the granular layer of the cerebellar cortex of subject 92.
IHC findings is shown in
Based on our analysis of these subjects, we found that 4 of 10 KSHV-seropositive individuals harbor KSHV DNA in the CNS. We also found that distinct brain compartments can be infected by KSHV but that the sites of infection vary among individuals. Immunolabeling of the HIV-negative, KSHV-seronegative control (subject 001; Supplementary Figure 1 ) and the HIVpositive, KSHV-seronegative control (data not shown) did not reveal any evidence of anti-LANA cross-reactivity in CNS tissue specimens, demonstrating the specificity of detection.
To identify the cell types harboring KSHV in the brain, we conducted dual-staining IF using CNS cell lineage-specific antibodies in combination with anti-LANA to identify the KSHV-infected cells. Antibodies against NeuN, GFAP, Olig2, Iba-1, CD20, VWF, and CD45 were used to identify neurons, astrocytes, oligodendrocytes, microglia/macrophages, B cells, endothelial cells, and leukocytes, respectively. Representative IF data from the cerebellum of subject 92 demonstrates that KSHV LANA signal colocalized with neuronal and, to a lesser extent, oligodendrocyte markers ( Figure 3A and 3B) but not with specific markers for astrocyte or microglia/macrophage lineages ( Figure 3C and 3D ). Our findings demonstrate that KSHV can infect neurons and potentially neuronal support cells in the brain parenchyma from KSHV-seropositive human brain tissues. No colocalization of KSHV LANA signal with B cells (CD20), endothelial cells (VWF), or lymphocytes (CD45) was detected in brain parenchymal tissue specimens (Supplementary Figure 2) .
To validate the apparent tropism of KSHV for neurons in human postmortem tissue specimens, primary human neurons were infected in vitro with 0.5 MOI of a recombinant KSHV.219 that expresses GFP during latent infection and RFP during lytic infection. At 72 hours after infection, primary neurons were fixed and stained with DAPI. Confocal microscopy was used to identify cells exhibiting in situ GFP expression as a surrogate marker for KSHV latent infection ( Figure 4A ). The expression of GFP in cells with obvious axonal and dendritic morphology demonstrates that KSHV was capable of latent infection of neurons in vitro. Since primary neuronal cell culture contains an enriched mixture of neurons and glial support cells, dual-color IF microscopy using α-LANA and a neuronal cell marker α-NeuN, as described above, was implemented to confirm that GFPexpressing cells were indeed neurons ( Figure 4B ). Despite clear identification of NeuN-positive cells in the mock-infected culture, no GFP or LANA staining was evident or colocalized with NeuN expression in those cultures ( Figure 4C ). Consistent with the finding from human postmortem tissue specimens, KSHV lytic expression was not detected in the infected primary neuron cultures (data not shown).
DISCUSSION
Currently, only a few PCR-based studies have suggested that the brain is susceptible to KSHV infection [28, 29, 31] . However, the detection of viral DNA by PCR alone is insufficient to demonstrate that the brain is susceptible because of the extensive vascularization of the tissue. One recent report, focused primarily on the potential neural tropism of KSHV's nearest gamma-herpesvirus relative, Epstein-Barr virus, also showed limited in vitro evidence that KSHV can infect the SH-SY5Y neuronal cell line [42] . Using PCR-based methods, they demonstrated expression of both LANA and the lytic protein K8. We detected infection in the same cell line, using the recombinant KSHV-GFP construct, but we were unable to unambiguously detect K8.1 protein expression by using immunofluorescence (data not shown). The results of these in vitro findings were largely consistent with our demonstration of latent infection in human primary neuron cultures, as shown by GFP expression from rKSHV.219 and colocalized LANA expression, but lytic reactivation was not observed.
Our data from human samples reveal that both KSHV DNA and LANA antigen can be detected in neurons and oligodendrocyte support cells in various brain regions. However, the brain tissue specimens we analyzed did not reveal any evidence of lytic reactivation. This is perhaps not surprising since our postmortem sampling did not include any individuals with symptomatic KS. In addition, our data showed that not all KSHV/HIV-coinfected patients harbor KSHV in the brain, suggesting that KSHV CNS localization could be related to their HIV disease. A broader panel of cases with defined HIV staging and with or without KS needs to be analyzed to confirm these findings. However, such postmortem CNS tissue specimens are not currently available. This study also raises additional questions that warrant further investigation. How frequently is the brain infected in the absence of HIV? Does KSHV demonstrate any preference for specific regions of the CNS or for specific types of neurons, as has been demonstrated for other herpesviruses? Finally, are there pathogenic or neurocognitive consequences of KSHV infection in the CNS?
The presence of KSHV in the brain suggests that the virus may potentially spread from the initial site of infection into the CNS. However, the mechanism for this dissemination remains unclear. It has been demonstrated that a number of viruses, including herpesviruses, undergo direct retrograde transport of virions through neural circuits from peripheral tissue specimens to the CNS [43] . Whether KSHV can access this type of transport route needs to be determined. In addition it is possible that the seeding of KSHV into the CNS could be mediated by peripheral blood cells. Although we did not detect KSHV infected extravasating cells in the tissue specimens analyzed, a lack of detection could be related to the timing of viral deposition or to the likelihood of detecting a rare event among a limited tissue sampling.
Given the association of HIV and KSHV infection, how HIV coinfection and immunosuppression may facilitate KSHV infection and the establishment of CNS infection needs to be analyzed in comparison to HIV-negative cases. It is plausible that HIV coinfection induces the expression of soluble mediators that alter the permeability of the blood brain barrier to enable KSHV or KSHV-infected leukocytes to achieve CNS infection. In the African setting, the role of HIV could be direct or indirect because HIV-positive individuals are often coinfected with other opportunistic infectious agents, including parasites. Indeed, it has been demonstrated that helminth infection associates with KSHV infection in Africa [44] . Whether the presence of these comorbidities influences KSHV neuroinvasion will need to be determined. In summary, our study is the first to demonstrate that brain tissues of Zambian HIV-infected patients are capable of harboring KSHV. KSHV infection is evident in CNS-resident cells, including neurons and oligodendrocytes. There appear to be differences in KSHV distribution in the brains among asymptomatic individuals, but more postmortem samples will be needed to determine whether particular tissues are selectively targeted. Likewise, brain tissue specimens need to be collected postmortem from HIV-positive and HIV-negative individuals with symptomatic KS to determine whether KSHV infection of the brain is different in more-advanced disease states and its dependence on HIV. Our investigation revealed little or no KSHV lytic antigen expression, but a larger number of samples or alternative organ/tissue culture methods may be required to determine whether CNS-resident cells can support lytic reactivation.
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